What is HC Wainwright’s Estimate for LXRX Q2 Earnings?

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) – Equities researchers at HC Wainwright increased their Q2 2025 earnings per share estimates for shares of Lexicon Pharmaceuticals in a report released on Wednesday, May 14th. HC Wainwright analyst J. Pantginis now expects that the biopharmaceutical company will earn ($0.08) per share for the quarter, up from their previous forecast of ($0.09). HC Wainwright currently has a “Buy” rating and a $4.00 target price on the stock. The consensus estimate for Lexicon Pharmaceuticals’ current full-year earnings is ($0.66) per share. HC Wainwright also issued estimates for Lexicon Pharmaceuticals’ Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at $0.10 EPS, FY2025 earnings at ($0.33) EPS and FY2026 earnings at ($0.34) EPS.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.03. Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. The business had revenue of $1.26 million during the quarter, compared to the consensus estimate of $1.26 million.

LXRX has been the subject of several other reports. Piper Sandler reduced their price objective on Lexicon Pharmaceuticals from $10.00 to $6.00 and set an “overweight” rating for the company in a research note on Friday, March 7th. Leerink Partnrs downgraded Lexicon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, March 5th. Needham & Company LLC reissued a “hold” rating on shares of Lexicon Pharmaceuticals in a research note on Monday, March 3rd. StockNews.com started coverage on Lexicon Pharmaceuticals in a research note on Monday, April 21st. They issued a “sell” rating for the company. Finally, Leerink Partners reissued a “market perform” rating and issued a $1.00 price objective (down from $2.00) on shares of Lexicon Pharmaceuticals in a research note on Tuesday, March 4th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, Lexicon Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $3.67.

Lexicon Pharmaceuticals Stock Up 1.0%

NASDAQ LXRX opened at $0.54 on Friday. The business has a fifty day moving average price of $0.53 and a 200 day moving average price of $0.71. Lexicon Pharmaceuticals has a one year low of $0.28 and a one year high of $2.45. The company has a debt-to-equity ratio of 0.56, a quick ratio of 7.43 and a current ratio of 7.45. The company has a market cap of $193.47 million, a P/E ratio of -0.71 and a beta of 1.07.

Institutional Trading of Lexicon Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the stock. Point72 Asset Management L.P. grew its holdings in Lexicon Pharmaceuticals by 630.7% in the 4th quarter. Point72 Asset Management L.P. now owns 8,988,421 shares of the biopharmaceutical company’s stock valued at $6,638,000 after buying an additional 7,758,371 shares in the last quarter. Schonfeld Strategic Advisors LLC grew its holdings in Lexicon Pharmaceuticals by 301.5% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 7,558,621 shares of the biopharmaceutical company’s stock valued at $5,582,000 after buying an additional 5,676,021 shares in the last quarter. Nantahala Capital Management LLC grew its holdings in Lexicon Pharmaceuticals by 186.6% in the 4th quarter. Nantahala Capital Management LLC now owns 6,604,150 shares of the biopharmaceutical company’s stock valued at $4,877,000 after buying an additional 4,300,000 shares in the last quarter. Northern Trust Corp grew its holdings in Lexicon Pharmaceuticals by 14.4% in the 4th quarter. Northern Trust Corp now owns 1,308,651 shares of the biopharmaceutical company’s stock valued at $966,000 after buying an additional 164,620 shares in the last quarter. Finally, AQR Capital Management LLC purchased a new stake in Lexicon Pharmaceuticals in the 1st quarter valued at $541,000. 74.70% of the stock is currently owned by hedge funds and other institutional investors.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.